ARID1A and endometrial cancer: Genomic analyses that detect alterations in TMB, MSI, and gene mutations including MLH1, TERT, POLD1, and POLE, IHC analyses that assess p53 and MMR protein expression, and other conventional IHC including PTEN and ARID1A exhibit significant potential as a practical diagnostic tool for determining endometrial cancer pathology.